Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | CD74 | P04233 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16263153 | 0.87 | CYP19A1 (0.57) | MEN1KMT2AHSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL12251051 | 0.87 | CYP19A1 (0.60) | MEN1KMT2ACYP19A1NPC1RAB9A | |
| SCHEMBL18922484 | 0.85 | HSP90AA1 (0.63) | MEN1KMT2AHSP90AA1HSP90AB1NPC1 | |
| SCHEMBL16264735 | 0.84 | MEN1 (0.50) | MEN1KMT2AHSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL18625953 | 0.81 | NAMPT (0.51) | MEN1KMT2AHSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL16263156 | 0.78 | HSP90AA1 (0.63) | MEN1KMT2AHSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL16263163 | 0.78 | ALOX5 (0.52) | MEN1KMT2AHSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL16263167 | 0.77 | CYP2D6 (0.47) | MEN1KMT2AHSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL22276766 | 0.76 | SCN4A (0.46) | MEN1KMT2ANPC1RAB9AKDR | |
| SCHEMBL22530280 | 0.76 | SRC (0.53) | MEN1KMT2AHSP90AA1HSP90AB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771389-B2 | Tylosin derivatives and method for preparation thereof | THE KITASAKO INSTITUTE (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9593140-B2 | Antibacterial tylosin derivatives and methods for their preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-9593140-B2 | Antibacterial tylosin derivatives and methods for their preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20160108077-A1 | TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF | THE KITASAKO INSTITUTE (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20140349954-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | ELANCO ANIMAL HEALTH GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108077-A1 | TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF | TMSB10, MLN, TMSB4X | MEN1 3564/4885KMT2A 2569/4885HSP90AA1 905/4885 |
| US-20140349954-A1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | MLN, TMSB10, TMSB4X | MEN1 3664/4885KMT2A 3403/4885HSP90AA1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.